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ABSTRACT 
Dengue is a viral disease characterized by mild febrile illness in the majority of cases. In a small 
percent of cases, it manifests more severe symptoms, and it can be fatal without proper treatment 
and support. It is a vector borne disease that is transmitted by the Aedes mosquitos. Currently up 
to 4 billion of the world’s population lives in areas at risk for dengue transmission. This represents 
a public health risk. 
The objective of this study was to evaluate the association of two single nucleotide 
polymorphisms (SNPs) located in the MRCI gene, rs2296414 and rs34039386, with dengue virus 
infection in a sample of patients from a cohort study of dengue patients and controls from Recife, 
Brazil. The MRCI gene codes for the mannose receptors of macrophages, which have been 
demonstrated to play an important role in viral infections. DNA was amplified using PCR. 
Genotyping of 179 individuals was done by three methods, fluorescence polarization, restriction 
digests, and sequencing. All samples were found to be in Hardy-Weinberg equilibrium across the 
sample population and when classified as cases of controls. No significant departures from Hardy-
Weinberg were seen when samples were broken down by disease status. Odds ratios were 
calculated with novel data and combined with data from a previous study. The previous study 
examined the same two polymorphisms using a different sample from the same cohort study.  A 
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statistically significant difference was found in the combined samples for the rs2296414 site with 
regards to case or control status, OR=1.46, p=.035. A statistically significant difference was also 
found for the rs34039386 site with regards to case/control status OR=2.76, p=.0029. This 
difference was only found in the novel data. 
Further research with larger samples sized is needed to continue to understand the 
relationships between these sites and dengue infection, as the sample size for this study was small. 
Even when combined with data from the previous study, the data set was not particularly large. 
The public health significance of this research is produced by the increasing global importance of 
dengue and the need for more effective treatments and the development of a vaccine; advancement 
of the understanding of the relationships between the dengue virus and the MRCI gene may lead 
to improvements in the treatments available and in the production of a vaccine with high efficacy. 
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1.0  INTRODUCTION 
The purpose of this project is to further evaluate a previous observation found in a study by Erin 
Cathcart. This goal of this protect was to generate more results to see if similar trends present as 
they did in the earlier work. The previous study showed a possible connection between several 
single nucleotide polymorphisms (SNPs) and an increased risk of severe dengue infection in a 
sample of patients from Brazil. In addition to an association between these mutations and severity, 
other associations, including age and sex, were also evaluated. To maintain the similarities and 
replicability of these two studies, these factors will also be investigated using this new sample. 
Both the samples used in the previous study and the samples used in this study were selected at 
random from the same larger sample of DNA collected from patients in Recife, Brazil. Controls 
for this study were selected from patients presenting to hospitals with other complaints who were 
determined to be dengue-free. Controls for the previous study were selected from a control group 
of patients who presented to the Brazilian health service to receive a yellow fever vaccine, and 
were determined to be free of dengue.  
Whenever possible, methodological approaches and data analysis techniques used in the 
previous work were used in this study as well. This was done to maintain as much similarity 
between the studies as possible to remove potential confounding factors when investigating the 
relationship of the results. Genotyping of patient samples was done using fluorescence polarization 
and restriction digest. Analysis of results was done in Excel and Stata, and several approaches 
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were taken, including Hardy-Weinberg equilibrium testing using chi-squared tests for significance, 
and odds ratios to determine the impact of different alleles on the presence or absence of disease 
and disease severity.   
1.1 BACKGROUND 
Dengue is a dynamic and ever-changing disease that has the potential to affect up to a half of the 
global population[1]. It represents an important global infection whose impact is growing and will 
only continue to grow. The factors that make dengue an important global health concern are diverse 
and multifaceted. While it is not a new disease on the global stage, in recent years, multiple factors 
have converged to cause a significant resurgence and spread. Not only is the distribution of dengue 
changing, but it is also intensifying as an infectious disease. This means there will be more cases, 
more serious infections, and more deaths from the virus as its epidemiology continues to change 
and evolve[1].  
1.1.1 Dengue Fever 
Epidemiology 
Current estimates disagree about the true global burden of dengue. However, despite the 
disagreements, no estimates place the burden as insignificant, and there is consensus that it is a 
growing and intensifying problem[2]. Morbidity and mortality estimates fall into a wide range 
depending on the source of the data. The World Health Organization (WHO) estimates that 2.5 
billion people live in areas currently at risk for dengue infection. This represents about 40% of the 
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global population[3]. The Center for Disease Control (CDC) estimates fall closely in line with the 
WHO, but they differ slightly when determining the number of countries that are currently at risk 
for dengue[2]. The WHO lists 100 countries as at risk and the CDC has an additional four listed[2]. 
These numbers may be underestimating the true burden of the disease. A study in 2012 by 
researchers from the United Kingdom and the United States estimated that the number of at-risk 
countries is higher. They found that 128 countries have good evidence of dengue occurrence[2]. 
The new list they generated using multiple levels of data and analysis found 36 countries with a 
good likelihood of dengue occurrence that were determined to be dengue free by the WHO[2]. 
This new work increases the potential percentage of the global population at risk to up to 3.97 
billion[2]. This is an extreme upper limit, but the evidence surrounding dengue infection makes it 
a plausible figure.  
As with many infectious diseases, it is difficult to determine the true level of dengue in the 
population. In fact, it is particularly difficult with dengue because of the similarity to other 
diseases, the remote locations of cases, and the high percent of subclinical infections[1, 2]. Early 
stages of dengue look like many other common viral illnesses[2]. Because of this, misdiagnosis is 
common[2]. An additional issue with determining the global burden of dengue is the often remote 
locations of the healthcare facilities where cases are treated. In many situations, the diagnostic 
capabilities of the facility are not able to handle the complicated diagnosis of dengue infection[2]. 
Finally, a large portion of dengue cases go unnoticed because they manifest as subclinical 
infections. Estimates vary, but between 50% and 80% of dengue infections may be asymptomatic 
or subclinical[4-6]. These cases may be entirely non-symptomatic, or they may manifest as a 
nondescript and mild febrile illness that does not lead people to seek out medical care[5, 6].  
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The highest estimates place the total number of yearly dengue cases at 390 million with 
approximately 25% (96 million) of them being apparent, clinical disease[7]. These numbers were 
arrived at in a study by Bhatt et al and published in Nature that looked to more accurately predict 
the global burden of dengue using sophisticated modelling techniques[7]  More conservative 
estimates from the WHO initially put that number considerably lower at 50 million cases[8], but 
recently they have updated information on the global burden of disease to include the numbers 
derived from Bhatt et al.’s study[3]. Of these 50-96 million clinical important cases, an 
approximate 500,000 are considered “severe dengue,” and are potentially life threatening[9]. Like 
many of the numbers surrounding dengue, the mortality rates are an estimate and may be 
significantly underreported. Deaths from dengue are likely between 20,000 and 25,000[10]. While 
this number is much lower than the deaths from other common illness like malaria[11], the WHO 
classified dengue as the most important mosquito-borne viral disease in the world in 2012[10]. As 
previously discussed, the reasons for this classification by the CDC are varied, but the most 
important to consider is the significant global spread in recent years and increased potential for 
continued spread and changing and evolving disease patterns[10]. 
Dengue is firmly established as being present in over 100 countries[1]. Asia, Africa, and 
the Americas bear the highest burdens of the disease, with Asia holding the highest percentage at 
around 70% of the global burden[1]. Africa accounts for 14% of the burden and the Americas 
13%[1]. Some of most affected countries include India, Mexico, and Brazil[1].  
The global distribution of dengue has changed significantly over the past four decades[10]. 
All evidence suggests that dengue has been an important human pathogen for several centuries -- 
perhaps longer, as records from 992 AD in China have cases with symptoms compatible with 
dengue[10]. Outbreaks consistent with dengue continued in the Americas through the 17th, 18th, 
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19th, and 20th centuries[10]. However, the virus responsible for dengue was not determined and 
isolated until 1943[12]. Between the end of the 1940’s and the 1970’s, dengue was present in only 
a small number of countries and in isolated outbreaks[10]. After the cessation of control measures 
in the 1970’s, dengue came back strongly over the next decades and is now firmly established as 
global disease[10]. Evidence strongly suggests that every WHO region has dengue transmission 
either in endemic or epidemic cycles[10]. 
Dengue is now hyperendemic, with locally acquired transmission in all but two countries 
in the Americas. Chile and Uruguay are the only countries in this region that have still not seen 
cases of locally-acquired dengue. Data suggests that there are close to two million cases annually 
in the American region countries[10]. 
Asia and the Pacific bear the largest brunt of the global dengue infections, as 75% of the 
exposed population lives in this region[10]. High morbidity and mortality is common in this 
region, and dengue represents the leading cause of deaths among children in the smaller region of 
southeast Asia[10]. In recent years, dengue has emerged in previously clear areas in China and 
Japan[1]. 
Dengue in Africa has been the subject of limited research, and is almost certainly 
underreported. At least 20 countries in Africa most likely have cases of locally-acquired dengue 
transmission and outbreaks have been recorded since as early as the 1960’s[10]. Despite no official 
cases reported to the WHO, laboratory cases have been confirmed. The high presence of other 
illness similar in symptomology and the poor resource settings account for the lack of reporting of 
dengue in this region[1]. 
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Dengue’s presence in Europe and Middle East has only been established more recently, 
but in the past several decades local transmission has occurred in at least three European countries, 
and many more in the Middle East[10]. 
Understanding the global spread of dengue is impossible without understanding its vector. 
The dengue virus is carried and spread by two distinct but very similar species of the Aedes 
mosquito, Aedes aegypti and Aedes albopictus [13]. Aedes aegypti is the primary vector for dengue 
and is more competent at transmitting the disease[10], but the presence of the alternative vector 
Aedes albopictus should not be discounted, as it has been shown to be an effective transmitter as 
well[10]. The global spread of dengue, however, closely follows the spread of Aedes aegypti. 
Control measures of this vector are what allowed dengue to temporarily become nonexistent in the 
majority of the Americas. It was only when vector control measures were ceased that both Aedes 
aegypti and dengue returned to this region of the world[12]. Both Aedes species are now fully 
established on at least parts of all continents except Antarctica[13]. Aedes aegypti prefers and 
thrives in subtropical and tropical climates, but Aedes albopictus is able to survive in much cooler 
climates with more dramatic seasonal fluctuations[13, 14].  
  The fact that the Aedes aegpyti mosquito is the one able to transmit the dengue virus is 
part of the disease’s remarkable ability to reach so many diverse regions. Aedes aegypti is a day-
biting mosquito that prefers to feed and breed in urban and semi-urban areas[1]. The combination 
of these factors means that dengue is common in settings with high population density. Human 
migration and travel are key factors in the spread and transmission of dengue[10]. Because the 
primary vector for the virus is well established in a wide range of regions, the potential for 
transmission is always there.  
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This is important to the transmission cycle for the dengue virus. Dengue follows a 
mosquito-to-person-to-mosquito cycle of transmission with no important intermediate hosts, as are 
common in many other vector-borne disease[3]. Infected humans are the primary carriers and 
multipliers for the virus[3]. A mosquito may become infected after biting an infected human during 
a period of high virus load known as viremia. This is typically a period 4-5 days after initial 
infection, but it can last up to 12 days[3, 9]. An infected mosquito will then go on to bite a new, 
susceptible host, and the transmission cycle will continue (see Figure 1.). 
Figure 1.  Dengue transmission cycle 
Virus 
Dengue belongs to a family of viruses known as the Flaviviradae, genus Flavivirus, which 
includes other important human pathogens such as Yellow Fever, West Nile, and Japanese 
Encephalitis[15]. Dengue itself has four phylogenetically distinct serotype labeled DENV1-4[16]. 
These four distinct types of dengue share about 65% of their genomes[9]. Despite sharing only a 
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little over half of their genomes, DENV1-4 are all highly related in their effects on their human 
targets and in their transmission and ecological niche[9]. 
Evidence strongly suggests that dengue was originally a monkey virus and was part of a 
sylvatic transmission cycle between non-human privates and mosquitoes. It is likely that the 
cross-species transmission to humans happened independently in all four of the distinct viral 
serotypes[16]. The emergence of the dengue virus into the human population most likely 
happened as recently as 500-1,000 years ago[9].  
In the evolutionary sense, this makes dengue a relative newcomer in the world of viruses. 
Occurring even more recently was the cross-species transmission from monkeys to humans. 
DENV2 made the jump approximately 320 years ago and DENV1 even more recently, around 
125 years[16]. The majority of the genetic diversity between dengue serotypes has occurred over 
the past 100 years[16]. Humans were likely incidental hosts in the sylvatic transmission cycle of 
the disease for the majority of its history[16]. The transition to the urban cycle of transmission 
observed today and the expansion of endemic areas was likely due to several factors, including a 
limiting number of nonhuman hosts, expansion of the vector, increased urbanization, and viral 
mutations[9, 10, 16]. 
The location of the emergence of the dengue virus is hard to determine with 100% 
confidence. Africa seems the obvious choice for several reasons. Part of the evidence supporting 
this assertion is that the primary vector for dengue, Aedes aegypti, is thought to have evolved in 
Africa. Additionally, a majority of the other mosquito-borne flaviviruses circulate primarily in 
Africa. This lends support to the claim of the flaviviridae family having evolved in this region, 
which would suggest that dengue may have evolved here as well[16]. 
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Despite the strong evidence supporting Africa as the cradle for the dengue virus, Asia 
also has a strong set of evidence backing it up as the likely origin; the prevalence and burden of 
dengue is highest in this region, and all four serotypes of dengue exist in both humans and 
monkeys in this area. The resolution of this debate will require continued research and larger 
sample bases from Africa, as samples from this region are limited, so the complete evidence may 
not be available[16].  
The dengue virus (DNV) is a single stranded RNA virus[9]. It is also a positive sense 
virus[17]. As with all viruses in the Flavivirus genus, dengue is an enveloped virus[17]. A 
lipopolysaccharide envelope surrounds a 40-50nm particle that is spherical in shape[9]. The 
RNA genome is around 11kb in length and encodes a total of only 10 proteins. Three of these 
proteins are structural, while the remaining seven proteins are non-structural[18].  The 11kb 
genome codes for a single polyprotein which is then broken down in the cytoplasm of the host 
cell into the separate structural and non-structural proteins[18]. The structural proteins include a 
capsid or C protein, a membrane or M protein, and an E or envelope protein[9, 17]. A host-
derived lipid bilayer surrounds the nucleocapsid which is derived of multiple copies of the C 
protein. Within this lipid layer, 180 copies of the smaller M protein (8kDa) and the larger E 
protein (52kDa) are anchored[19]. The E protein is composed of three distinct domains, and its 
unique structure plays an important role in different stages of infection. The E protein is arranged 
in a herringbone pattern of 90 head-to-tail dimers organized in sets of three and positioned 
parallel to the viral surface. The non-structural proteins are NS1, NS2a, NS2b, NS3, NS4a, 
NS4b, and NS5 (see Figure 2). These proteins are all responsible for parts of  the viral life cycle 
including viral replication, virion assembly, and escape from the host’s immune system[18]. 
NS2A is responsible for blocking host interferon (INF) signaling. NS2A, NS4A, NS4B, and NS5 
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also work to block INF by reducing STAT activation[19]. NS1 is particularly important in 
dengue pathogenesis and diagnosis[18, 19].  
Figure 2.  Dengue genome 
The viral life cycle for dengue is complex, and elements of it are still not understood fully 
After viral entry into the host cell, a single polyprotein is produced from the 11kb genome, and is 
then processed by both host and virus proteases into the separate proteins[19]. The variety of NS 
proteins are responsible for replication of the viral genome after initial protein processing and 
folding is completed. After the production of new viral RNA, it is wrapped by the C protein 
capsid. The PreM and E proteins are arranged facing into the lumen of endoplasmic reticulum 
and formed into heterodimers. The processes of the association with the nucleocapsid are still 
unclear[19].  
Pathogenesis  
Primary cellular targets for DNV are of the mononuclear phagocyte lineage and include 
monocytes, macrophages, and dendritic cells[19]. Langerhans cells and dendritic cells residing in 
the skin are often the site of the first infection[19]. Viral entry into this primary cellular target is 
the most important factor in establishing infection, but it is also the least understood[18]. Viral 
entry involve many possible cellular targets[18, 19]. The process begins and is mediated by the 
viral E glycoprotein. These viral proteins bind to multiple cellular receptors, some known and 
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some unknown. These will be discussed in more detail later, as they are an important component 
of this research.  
There is strong evidence to suggest that the primary path for cellular entry by the dengue 
virus is receptor initiated: clathrin mediated endocytosis[18, 19]. Membrane fusion allows the viral 
RNA to enter the host cell[18]. More recent research has suggested that in addition to clathrin 
mediated uptake, certain strains of the dengue virus are able to enter the cell through clathrin 
independent pathways[19]. This is achieved by DENV-2 dynamin and is also completely 
independent of micropinocytosis or phagocytosis[18]. 
Cellular targets of the dengue virus are still not well-established and are an important area 
of research focus. On initial infection of immature dendritic cells in the skin, the virus enters the 
cell using cell surface molecules known as non-specific receptor dendritic cell-specific ICAM3-
grabbing non-integrin (DC-SIGN)[18]. DC-SIGN is a C-type lectin transmembrane protein[18]. 
DC-SIGN is expressed in abundance in these immature dendritic cells and is involved in their 
migration, as well as T-cell priming, antigen recognition, and presentation[18]. Other important 
possible cellular receptors include heparin sulfate, CD14, HSP90/HSP70, the glucose protein 78, 
the TIM and TAM proteins, the laminin receptor, and (most importantly for our discussion) the 
mannose receptor[18], which will be discussed in more detail later. 
After the initial infection of the immature dendritic cells in the skin, the virus is taken up 
and disseminated to the lymph nodes. After dissemination, it continues to target cells of the 
mononuclear lineage. This stage is when the pathogenesis of the infection becomes known as 
macrophages begin to secrete inflammatory mediators[17].  
The pathogenesis and host immune response of the dengue infection are closely tied 
together, and one must be discussed when discussing the other. Multiple theories have been 
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proposed to explain the process of immunopathogenesis and the progression of the infection, and 
each must be examined to fully understand this complex infectious process. Antibody-mediated or 
dependent enhancement theory, altered peptide ligand theory, and the cytokine storm theory will 
all be discussed. First, a brief overview of the immune response is necessary.  
As with all infections, the body’s initial defense against the virus is the components of the 
innate immune system. The initial defense after infection is the production of interferons: type I 
and type II interferons are produced within hours by all dengue infected cells[19]. During this time 
period of infection, natural killer cells are also activated. This whole process and the production 
of interferons is mediated by viral communication with pathogen recognition receptors on the 
cellular surfaces. Receptors involved in this include C-type lectins (DC-SIGN) and toll-like 
receptors (TLR), specifically TLR3 and TLR7. Pathogen recognition receptors begin a 
transcription cascade using various transcription factors which will ultimately lead to the 
production of interferons[19]. This stage also represents the first place the dengue virus is able to 
circumvent the immune system’s response to its presence. The dengue virus is able to obstruct the 
interferon-alpha mediated innate antiviral response. This is done using several of its non-structural 
genes, particularly NS2A, NS4A,B and NS5[19]. 
Approximately six days following infection, the humoral immune response begins. 
Antigen presentation to cells of the humoral immune system initiates this process. The antibodies 
generated by B cells are mostly targeted at the viral envelope glycoproteins, the pre-membrane 
glycoproteins, and NS1. NS1 is both secreted by and expressed on the surface of infected cells[19]. 
The antibody production works to neutralize viral infection in several ways. Antibody production 
against NS1 starts the complement-mediated lysis of viral infected cells. Antibodies against the 
other protein types most likely work to directly influence the infectious ability of the virus, as well 
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as neutralization. Both strongly and weakly neutralizing antibodies are produced, and the number 
of them needed to effectively work to neutralize the virus is less or more respectively[19]. The 
most effective antibodies are produced to strain specific differences and are specific to the third 
domain of the envelope protein, whereas weaker antibodies are directed at the second domain. 
These neutralizing antibodies have been shown to work through blocking viral attachment to 
cellular receptors and by impeding other steps in the process of viral entry into the host cells[19]. 
T cell involvement in dengue is not well understood. Some studies have suggested that 
CD8+ T cells may play an important role in immune defense against the dengue virus, but limited 
models still leave questions surrounding this process. In contrast to the protective quality of T cell 
response, T cell responses may be responsible for the pathogenesis seen in the more severe cases 
of dengue infection[17, 19]. This topic will be discussed in more detail along with the various 
theories of pathogenesis. 
One of the defining factors of dengue is the fact that secondary infection with a different 
strain is often responsible for a much more severe progression of the disease. Multiple 
epidemiological studies have corroborated this phenomenon[19]. The severe forms of dengue, 
dengue hemorrhagic fever and dengue shock syndrome, are much more likely to occur when a 
patient has had a previous dengue infection and is re-infected, this time with a different strain. 
Several theories have been proposed to explain this phenomenon and the process that leads to 
severe symptoms seen in dengue hemorrhagic fever and dengue shock syndrome.  
The original and still widely accepted hypothesis to explain this is the theory of antibody-
mediate enhancement or antibody-determined enhancement (ADE). This theory was first 
popularized by Halstead and O’Rourke in 1977[17] and seeks to explain why a secondary infection 
with a different serotype of the same virus would lead to more serious disease instead of protective 
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immunity, as is often the case with secondary infections, even when the serotypes are different. 
The primary tenet of this hypothesis is that something in the body’s secondary immune response 
to the pathogen goes wrong, producing the symptoms associated with severe dengue. The most 
important component of this occurrence has been shown to be the presence of Fc receptors on cells 
of the mononuclear lineage, including dendritic cells, monocytes, and macrophages[20]. 
Antibodies produced in higher levels from memory B cells act to specifically direct the virus to 
cells that express Fc receptors, which happen to also be the primary target for the virus. This creates 
a higher viral load throughout the body and the impairment of several types of immune system 
cells[19, 20]. This enhancement of viral uptake seems to be facilitated primarily by enhancing 
immunoglobulin G (IgG), but IgM and complement factor 3 (C3) have also been demonstrated to 
be able to achieve the same ends[20]. These enhancing antibodies pull the virus into contact with 
the cellular surface of cells expressing Fc receptors. It seems like viral uptake into the cell is not 
achieved by the Fc receptors alone, but requires working with a normal viral receptor as a co-
receptor.  
This process alone does not explain the whole story behind the progression to severe 
disease, and other theories are needed to supplement it. It is also important to note that not every 
secondary infection leads to more severe disease; in fact, in a majority of cases it still produces an 
asymptomatic or mild infection, as is true for dengue rates as a whole[20]. 
The potential role of T cells in the production of symptoms during severe dengue infection 
is explained in the theory of “original antigenic sin” (OAS). The hypothesis of original antigenic 
sin is that on secondary infection by a new serotype of the dengue virus, the host’s immune system 
activates memory T cells from previous infection. These T cells possess too low an affinity for the 
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new serotype present. This inappropriate response hinders the development of a strong enough 
response with high affinity, and instead leads to a state of immunopathology[17].  
Closely tied into original antigenic sin is the cytokine storm. This is theorized to occur 
when the over-activation of T cells causes the production of vast quantities of antiviral cytokines. 
These cytokines, which under normal levels are vital for fighting infections, result in cellular 
damage. It is this process that is believed to be responsible for the loss of endothelial integrity, 
vascular leakage and hemorrhage that is a hallmark of severe dengue infections[19]. This abnormal 
immune response results in high levels of multiple cytokines including TNF-alpha, IFN-gamma, 
IFN-alpha, IL-1, IL-2, Il-4, IL-6, Il-7, Il-8, IL-10, Il-13, and Il-18[19]. This increased cytokine 
production cannot be fully explained by OAS only, and other factors including ADE are also likely 
causing it to a certain degree. [3, 17, 19, 20]. 
Clinical 
More often than not, dengue manifests as an uncomplicated febrile disease with minor symptoms, 
similar to the flu and many viral illness. It is considered a self-limiting illness, meaning that in 
most cases it will resolve without medical intervention and the patient will recover. This self-
limiting illness usually last only a week, with some symptoms lingering longer in some 
populations[6]. Dengue infection is classified into three stages by the World Health Organization, 
1.) febrile, 2.) critical, and  3.) recovery[6].  
The first stage in the natural history of dengue is the febrile stage. In addition to the high 
fever that gives this stage its name, this stage also comes with other symptoms. Frequently seen 
symptoms include fatigue, rash, joint and muscle pain, and headache. Gastrointestinal symptoms 
are less common but do occur including nausea and vomiting[6]. A critical component of this 
stage that is an important factor in diagnosis and transmission is the high viral load in the blood. 
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Viremia and a low platelet count are present during this stage of the disease[6]. The febrile stage 
typically last 2-7 days[6].   
The disappearance of detectible viremia and a rapidly decreasing platelet count mark the 
beginning of the second stage. The critical stage is named such because it is this stage that 
determines the progression of the disease[6]. Capillary permeability present during the critical 
stage presents as a rising hematocrit and decreasing platelets. This stage resolves on its own in 
24-48 hours in most cases but in a minority of cases the symptoms may progress to internal 
bleeding and shock which are the hallmarks of the more severe forms of dengue, dengue 
hemorrhagic fever and dengue shock syndrome[6].  
Patients progress to the final stage of the disease if they do not develop either of the 
severe complications of the critical stage. During the recovery phase symptoms improve 
markedly and fluid lost during times of high capillary permeability is reabsorbed. Some 
symptoms may continue during the recovery phase and after, especially fatigue[6].  
The clinical classifications of dengue have been revised and reworked several times 
during the history of the disease. The current classifications were set in 2009 by the World 
Health Organization and includes three new categories for dengue: dengue without warning 
signs, dengue with warning signs, and dengue hemorrhagic fever[6]. These new classifications 
were revised from the previously used ones implemented in 1997. The 1997 classifications 
include, dengue fever (DF), dengue hemorrhagic fever (DHF), and dengue shock syndrome 
(DSS)[6]. The presence of plasma leakage in dengue patients is what classifies DHF and the 
progression to bleeding and shock is classified as DSS[6]. These classifications were modified to 
the current 2009 recommendations because of concerns that the older categories did not do an 
adequate job of describing a classifying patients with more serious disease[6]. Several concerns 
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were raised about the 1997 classifications which were first adopted in 1975 and modified several 
times before reaching their final 1997 configuration[21]. Multiple case studies over the years 
after the 1997 adoption of classifications lead to a set of concerns about their applicability and 
usefulness. These concerns included the 1997 classifications being not well linked to disease 
severity, the potential for misdirecting clinicians in identifying severe disease, the fact that it is 
difficult to apply correctly because of the availability of tests and level of difficulty to conduct 
them, the fact that it is not useful for triaging in outbreak scenarios, and it leading to global 
differences in reporting because of the difficulty and availability of the test required to classify 
the cases[21]. The primary focus of the new system derived in 2009 is to reduce the difficulty in 
classifying cases and allow for better global reporting and reduction in mortality and 
morbidity[21]. The 2009 classifications are based on the presence or absence of several clinical 
signs and symptoms or laboratory tests. The full classification can be seen in Figure 3. Dengue 
without warning signs or “probable” dengue must meet several criteria, as patients must present 
with a fever and two or more other symptoms including aches and pain, leukopenia, nausea and 
vomiting, and rash[6]. In addition to the presence of these symptoms, travel or living in a 
dengue-endemic area is required[6]. It is also possible to use lab confirmation to confirm cases as 
well[6]. To be classified as dengue with warning signs, a patient must present with the above set 
of symptoms as well as one or more from a list considered warning symptoms for progression to 
severe disease[6]. These warning symptoms include abdominal pain or tenderness, persistent 
vomiting, clinical fluid accumulation, mucosal bleed, lethargy, and liver enlargement[6]. Three 
criteria are required for a patient to be classified as having severe dengue: severe plasma leakage, 
severe bleeding, and severe organ impairment[6]. These criteria can be assessed by laboratory 
test of clinician evaluation[6]. Treatment of dengue is primarily supportive. Close fluid 
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management is critical in cases of dengue with warning signs, in which cases the patients are 
generally admitted to the hospital to manage care. Other supportive measures including pain 
management are used to manage dengue cases[6]. For the purpose of our study, special 
classifications common to Brazil will be used. These include Dengue Fever, Complicated 
Dengue, and Dengue Hemorrhagic Fever. 
Figure 3.  2009 WHO classifications 
1.1.2 MRC1 and the Mannose Receptor 
The mannose receptor has been shown to have roles in immunity as well as specifically in viral 
infections. The mannose receptor is made up of C-type lectin proteins. C-lectin type proteins are 
transmembrane proteins expressed on multiple cell type surfaces[22]. These are especially 
important on the surface of dendritic cells and macrophages. The mannose receptor is composed 
of three extracellular domains, a cysteine rich domain (CR), a fibronectin type 2 repeat domain 
(FNII), and a carbohydrate recognition domain (CRD). The receptor possesses one of each of the 
CR and FNII, but has eight CRDs. The mannose receptor has the ability to bind both endogenous 
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and exogenous ligands, which supports its ability to perform multiple functions within the immune 
system[22, 23].   
Studies have shown that the mannose receptor may play a role in cell-cell signaling, innate 
immunity, antigen presentation, and infection of macrophages. Evidence suggests that the 
mannose receptor acts as pattern recognition receptor and may play a role within the innate 
immune system’s ability to fight microbial infections[22, 23]. An important piece of evidence that 
supports the mannose receptor being a good candidate for a method of entry of pathogens into 
macrophages is the fact that the mannose receptor is regularly internalized into the cell and 
recycled back out to the cell surface without the necessity of a substrate binding [22, 23].  
The role of mannose receptors in the process of viral infections is still not well understood, 
but in recent years more and more research has been conduct to determine what role or roles it 
may play in different viral infections. Important to our discussing is recent findings linking the 
mannose receptor to dengue infection. Recent evidence has pointed to the mannose receptors of 
the macrophages and monocytes as being an important cellular target for the dengue virus. A study 
done in 2008 by Miller et al out of the University of Oxford found that all four serotypes of dengue 
are able to bind to macrophages and monocytes mannose receptors [22]. Not only is dengue able 
to find to the mannose receptor, but active infection of the cells was found shortly after 
binding[24]. This may indicate that the mannose receptor is necessary to infect macrophages[24]. 
This study has critical implications to this research, as it shows the mannose receptor may play a 
role in dengue’s ability to infect host cells. These findings present the basis of the rationale for 
investigating the role of these specific polymorphisms of the MRCI gene and their relationship 
with dengue disease. 
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The mannose receptor of macrophages is coded for by the MRCI gene. It is located on 
chromosome 10 on the p arm at location 13[25]. This region of chromosome 10 has also been 
shown to have genes that code for a few other C-type lectin proteins. The MRCI gene is composed 
of 30 exons and 29 introns. All of the 30 exons are separated by an intron. Exons 3 and 7 are 
important for this discussion, as they contain the single nucleotide polymorphisms (SNPs) of 
interest to this study. Exon 3 codes for the one fibronectin type II repeat domain of the mannose 
receptor. Exon 7 codes for the carbohydrate recognition domain 2 of the mannose receptor. This 
domain is not fully coded by exon 7; other parts of it are coded by exons 8 and 9. The fibronectin 
type II repeat domain coded for by exon 3 is extracellular and believed to be necessary and 
sufficient for the binding of collagen. The carbohydrate recognition domain 2 is particularly 
important for infection[25, 26].  
It is important to note that polymorphisms of the MRCI gene have been linked to several 
infectious diseases by previous studies[27-29]. Two studies in Chinese populations found 
significant associations between SNPs in exon 7 of MRCI and susceptibility to pulmonary 
tuberculosis. One study discovered that SNPs in this exon may confer protection against 
pulmonary TB[29]. Another study conducted on other SNPs found that they are significantly 
associated with susceptibility to tuberculosis[27]. Another study found association between 
leprosy susceptibility and polymorphism of exon 7 of MRCI[28]. 
1.1.3 Single Nucleotide Polymorphisms (SNPs) 
Two SNPs of the MRCI gene were investigated for a relationship with dengue disease. One 
polymorphism is located on exon 3, and the other on exon 7. The first SNP of exon 3, rs2296414, 
is a change from C to T. It is a missense mutation that results in an amino acid change in the protein 
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from a threonine to asparagine[30]. This exon codes for fibronectin type II repeat domain[24]. The 
SNP of exon 7, rs34039386, is also a missense mutation. An A is changed to a G and results in an 
amino acid sequence change from a glycine to a serine[24, 31]. As previously mentioned, it codes 
for a portion of the second carbohydrate recognition domain of the mannose receptor[24]. For both 
of these specific mutations, the clinical significance is unknown[19, 30, 31].  
1.2 GOALS/HYPOTHESIS 
1.2.1 What: Goals  
The primary goals of this study are to twofold. The primary goal is to analyze a subset of samples 
from a patient cohort from Brazil. The aim of this analysis is to determine if there is a relationship 
present between the two SNPs in MRCI and dengue infection or dengue severity. The secondary 
goal is to produce further results to test the association found previously from a different sub-
sample of the same cohort. Along with the novel analysis, data from the original study will be 
combined with data from this study to see if results remain consistent, and to increase the overall 
sample size. As with this current study, the previous study looked for an association between the 
SNPs and dengue infection and severity in this population.  
1.2.2 How: Methodological Approaches. 
This research was conducted by genotyping a subset of samples from the patient cohort to 
determine their genotypes at the two locations of interest. The genotyping was done using 
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fluorescence polarization, restriction digest, and whole genome sequencing. After genotyping, the 
data was analyzed to test for Hardy-Weinberg equilibrium. This is a standard test performed on 
genotypic data, and departure from it could indicate either that genotyping errors had taken place, 
that demographic factors exist in our sample set that perturb equilibrium, or that one genotype may 
confer a selective advantage. Significance testing for Hardy-Weinberg was done using chi-squared 
analysis. In addition to this test, odds ratios were done to identify dominant/recessive relationship 
between the disease outcome and the different alleles present at the sites of interest. Odds ratios 
were done for the novel data alone, and then were retested after combining the novel data with 
data from the previous study.  
1.2.3 Why: The supporting evidence  
Previous studies have shown that there may be associations between SNPs in the MRCI gene and 
infectious disease susceptibility and severity [27-29]. Three studies have found evidence 
supporting this: one found an association between leprosy susceptibility and SNPs of MRCI [28], 
and two others found an association between MRCI polymorphisms and tuberculosis 
susceptibility[27, 29]. Especially important for this research is the fact that the macrophage 
mannose receptor which the MRCI gene codes for has been shown to mediate infection with the 
dengue virus[24], so it is reasonable to hypothesize that mutations on that gene may affect dengue 
infection. 
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2.0  METHODS 
The 187 DNA samples for this study were pre-extracted on-site in Brazil. The samples arrived 
dehydrated, so rehydration was required before genotyping procedures could begin. The 
concentration of the samples was tested and determined by the Nanodrop 1000 spectrometer. The 
concentration of the samples was 100ng/ul. After determining the samples’ concentration, primers 
were then selected for both of the SNPs locations. Fluorescence polarization and restriction digests 
were used to sequence the sample DNA. A database was created with the sample’s genotype at 
both SNPs, which also contained important clinical and demographic information. Analysis was 
completed using Excel as a data organizer and test generator. Chi-Squared analysis and Odds 
Ratios were used to determine the significance between SNP and disease status.  
2.1 SAMPLE SELECTION 
The samples used in these studies were randomly selected from a large cohort study of dengue 
patients conducted in Recife, Brazil. The collection was done by the Department of Virology at 
the Aggeu Magalhães Research Center[32, 33], which is part of the National Oswaldo Cruz 
Foundation, also known as Fiocruz. The recruitment of the participants occurred between 2005 
and 2009 with three hospitals involved in the study: The Instituto Materno Infantil de Pernambuco, 
Hospital Esperanca, and Hospital Santa Joana. Blood samples were collected on admission to any 
of these hospitals if dengue was suspected. Samples were collected at admission and several times 
after during the patients’ stay[32, 33]. Controls were patients in the same hospitals that presented 
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with febrile illnesses that were determined to not be dengue. They were additionally tested to 
determine that they had not had previous infection with dengue. 
The clinical classification of the patient was determined by following them over the course 
of the disease progression. New clinical classifications were developed for this study, as some 
cases did not meet the definition for WHO classifications of dengue fever, dengue hemorrhagic 
fever, or dengue shock syndrome. The classifications developed for the study were dengue, 
complicated dengue, and dengue hemorrhagic fever. These classifications were created before the 
revised WHO organization classifications were developed in 2009. The classifications used in this 
study closely follow those from 1997, with the added category of complicated dengue.  
Case samples were also classified as either primary infection or secondary infection. Real 
Time-PCR, ELISA, and viral isolation were used to determine the infection as primary or 
secondary by analyzing the presence or absence of antibodies. Primary patients are classified as 
being without dengue specific IgG antibodies in acute serum during the first days after the 
beginning of a fever, but with dengue specific IgM followed by the development of an anti-dengue 
IgG response during recovery(8). Secondary cases were classified which had detectable anti-
dengue IgG in the acute serum samples, but did not have anti-dengue IgM followed by the 
development of an anti-dengue IgM response in recovery[32]. 
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2.2 SITE SELECTION  
2.2.1 Single Nucleotide Polymorphism Selection  
The SNPs selected for this project were chosen for various reasons. Because one of the aims of 
this study was to replicate results from previous work it was necessary to select the same sites that 
were used in that study[34]. The sites were originally selected for several additional reasons. 
RS2296414 has been studied previously, and several studies describe its allele frequencies in 
different population. The approximate frequency of the C allele is 0.854 and 0.146 for the T allele 
globally[30]. Rs34039386 was originally selected because of an association found in a previous 
study that showed it was significantly associated with a decreased risk of infection with 
Mycobacterium tuberculosis[29]. Because of the previously seen association with an infectious 
disease, it was speculated that it may affect the susceptibility to other infectious agents as well.  
2.3 GENOTYPING 
DNA from 179 samples was received pre-extracted. Before analysis could begin it was necessary 
to rehydrate the samples as they had been dehydrated for shipping. Each samples was rehydrated 
with 10micolitres of deionized water and the concentrations of DNA were tested on a random 
sample of the sample before proceeding. It was determined that the samples contained 
100ng/micolitre. This was quantified using the Nanodrop 1000 spectrometer.  
Genotyping was completed using two methods: fluorescence polarization (FP) analysis and 
restriction digests. FP analysis was the first method used. When the results from some of the 
 25 
samples were not clear enough, restriction digest was used to confirm the genotypes of the 
remaining samples. Polymerase chain reaction was the first step performed for both of the 
analyses.  
2.3.1 Polymerase Chain Reaction 
Polymerase chain reaction was first used to amplify the DNA before genotyping. Taq 
polymerase was used for this PCR reaction. Taq, deoxynucleoside triphosphates, buffer solution, 
bivalent cations of magnesium, and sense and antisense primers were added to the DNA. Primers 
selected for this analysis were as follows: for rs2294614, sense-CAC TCA CAT TCC AAG TTC 
and antisense-GTC AGT AGT GGT TCC GCA C and for rs34039386, sense-GTG ATG TGC 
CTA CTC ACT G and antisense-GTA GAA AGG GGT GCT CCC. Rs2294614 samples were 
run with 2.5mg of magnesium chloride at 54 degrees Celsius. Rs34039386 samples were run 
with 2.5mg of magnesium chloride at 56 degrees Celsius.  
2.3.2 Fluorescence Polarization 
The primary method used to determine the genotypes of the samples was fluorescence polarization. 
This was done following the method of Chen et al[35]. After amplification by PCR, a cleanup step 
was performed with exonuclease I and shrimp alkaline phosphatase. This step is done to remove 
any nucleotide bases that were unused in the PCR amplification step. Next, the samples were 
cycled with thermosequenase, a heat-activated enzyme, FP probes and allele specific dyes. The 
FB probes used in this study were AGG CAA TGC CAA TGG AGC AA for RS2994614 and GTG 
GAT ACT TGT GAG GTC AC for rs34039386. A 1:8 CT dye was used. It was composed of r110 
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and TAMRA dye. After a final cycle, the samples were run through an FP machine. Data from this 
was collected and analyzed using the allele caller software. This software produces scatter plots of 
sample genotypes, from which genotypes can then be manually determined. A total of four plots 
were produced using this method, which corresponds to the four trays of samples that were run 
through. Two trays were done per RS number to cover the total 179 samples.  
2.3.3 Restriction Digest 
After FP analysis was completed, it was determined that some of the samples were not genotyped 
adequately with the FP analysis, and to fully determine their genotype at the two SNPs more 
analysis was needed. Restriction digest was used to complete this additional analysis. Restriction 
digest was only used to genotype samples for rs34039386. In total, 16 samples from tray 1 and a 
full tray 2 were done using this technique. A total of 98 samples were typed using restriction digest. 
AciI at a 1x concentration was used in this digest. They were run over night (12-18 hours) at 39 
degrees Celsius. AciI is a an enzyme that digests the 589 base pair fragment amplified by PCR and 
produces cut fragments 350 and 239 base pairs long when a G allele is there. The occurrence of 
the A allele produces no cuts, and the resulting fragment stays 589 base pairs long. DNA fragments 
produced by the restriction digest were electrophoresed in a 2% agarose gel containing ethidium 
bromide for approximately 1 hour and visualized by UV trans-illumination using a Stratagene 
Eagle Eye II camera and read with Biorad Quantity One 4.4.0 software.  
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2.3.4 Sequencing  
Finally, a few samples that were resistant to both previous forms of genotyping were genotyped 
with sequencing. Forty samples were genotyped using this method. The whole product of the initial 
PCR was sequenced. Sequencing was done on site at the University of Pittsburgh’s sequencer.  
2.4 STATISTICAL ANALYSIS 
2.4.1 Population Demographics 
All samples were analyzed for demographic characteristics using Microsoft Excel software. 
Samples were categorized by gender, age, and disease status to determine the characteristics of the 
particular sample of the population represented in this study. 
2.4.2 Hardy-Weinberg Equilibrium  
Observed genotype frequencies for each SNP of interest and for each disease status were used to 
calculate allele frequencies. The allele frequencies were then used to calculate the expected 
genotype frequencies in the sample under the Hardy-Weinberg equilibrium. Observed and 
expected genotype frequencies were then analyzed for significance using chi-squared tests.  
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2.4.3 Odds Ratios 
In addition to chi-squared tests, odds ratios were calculated to determine the odds of disease based 
on observed genotypes. Odd ratios were conducted using STATA and Excel software. 
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3.0  RESULTS 
3.1 POPULATION CHARACTERISTICS 
3.1.1 Demographics  
Population demographics were analyzed. The sample selected represented a closely even split 
between males and females, with just slightly more males represented. Females made up 41.9% of 
the population and males represented 58.1%. A wide spread of ages is seen in this population as 
well; the highest percent of the population is in the 40-49 group, followed by the 20-29 group. This 
distribution is similar to what is seen in the total population of Brazil. The lowest percentages are 
seen in the youngest and oldest groups. Figure 4 shows the distribution of the population by age 
and sex.  In table 1, the total percent of each sex and age group are available. 
 
Figure 4.  Age and sex distribution 
0
5
10
15
20
25
30
35
0-
19
20
-2
9
30
-3
9
40
-4
9
50
-5
9
60
-6
9
70
-7
9
80
-8
9
Age
Female
Male
 31 
 
 
Table 1.  Age and sex distribution 
 
 
 
 
 
 
The population was also examined with regards to disease status by sex and age. Females represent 
a slightly larger portion of the controls (ND) than males. They also represent higher proportions 
of dengue fever (DF) and dengue hemorrhagic fever (DHF). The only disease status where males 
have a higher proportion is complicated dengue (CD). Figure 5 shows the distribution. Examining 
the data by sex and age gives interesting information on the population characteristics as well. 
 
Figure 5.  Distribution of diseases in the sexes 
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Among females (figure 6), the highest counts of DHF are seen in the older age groups. Both DF 
and CD dengue spike among the young to middle age adults. Cases are evenly distributed, with 
the notable exception of the youngest age group. The males in this sample are more skewed to the 
younger age groups (figure 7). The highest numbers of all forms of dengue can be seen in young 
to middle age adults. DF peaks in 40-49, CD peaks at 20-29 and 40-49, and DHF from 30-49. The 
controls in the males are not as evenly distributed as in the female samples. 
 
Figure 6.   Disease status by age: female 
 
Figure 7.  Disease status by age: males 
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Because sex can be a confounder when investigating the relationship between genotype 
and disease, it was first important to determine if there was any association present in the 
population between sex and case/control status. An odds ratio was calculated to test this. No 
significant result was found with regards to sex and disease status (table 2).    
Table 2.  Odds ratio for sex and case/control status 
 Cases Controls Odds 
Ratio 
95% CI P 
Female 52 23 
0.83 0.43-1.60 0.58 Male 76 28 
3.1.2 Genotype Frequencies  
The genotype frequencies for rs2996414 in the whole sample were .65 for CC, .33 for CT, and 
.017 for TT. These are summarized in figure 8. Genotype frequencies were also examined by 
disease status to see if there were visible differences in the frequencies between different levels of 
disease. The summary information for this can be found in table 3. 
 
Figure 8.  Genotype frequencies for rs2296414 
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Table 3.  Genotypes by diagnosis: rs2296414 
 Dengue Diagnosis  
Genotype DF CD DHF ND TOTAL 
CC 27 54 7 27 115 
CT 10 24 2 23 59 
TT 0 1 2 0 3 
Total 37 79 11 50 177 
 
The TT genotype is seen in the highest amount in DHF cases. The overall number of DHF 
cases is very small, however, because of the rare nature of the condition. CC and CT are relatively 
even throughout the diagnoses, with CT being slightly higher in ND and CC being slightly higher 
in DF (figure 9).  
 
Figure 9.  Genotype by dengue diagnosis: rs2296414 
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amount in DF and CD. The AG genotype is evenly distributed among the cases, but is less frequent 
in the control samples. Likewise, GG is constant among the cases, but higher in the controls (figure 
11).  
Table 4.  Genotype by dengue diagnosis: rs3409386 
 Dengue Diagnosis  
Genotype DF CD DHF ND TOTAL 
GG 15 27 4 31 77 
AG 16 39 6 16 77 
AA 7 13 1 4 25 
 38 79 11 51 179 
 
 
Figure 10.  Genotype frequencies for rs3409386 
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Figure 11.  Genotypes by dengue diagnosis: rs34039386 
3.1.3 Allele Frequencies  
In addition to investigating genotype frequencies, it was also necessary to study the allele 
frequencies and how they might differ between diagnoses. The SNP rs2296414 was studied first. 
The frequency of the T allele in the whole sample population is .18 or 18%. The frequency of the 
C allele is .82 or 82% (figure 12). 
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Figure 12.  Allele Frequencies for rs2296414 
When broken down by diagnosis, not much difference can be seen in the allele frequencies. 
There is a slightly higher proportion of T allele in the DHF cases than is seen in other diagnoses. 
The proportion of the T allele is lowest in DF cases. The proportion of the C allele is highest in 
DF cases and lowest in DHF cases (figure 13).  
The proportion of the A allele of rs34039386 is .35 or 35% in the sample population and 
the frequency of the G allele is .65 or 65% (figure 14). When broken down by diagnosis, there is 
a somewhat clearer difference in the proportion of alleles than was seen at the other site. The 
highest proportion of A alleles is seen in CD cases and the lowest is seen in ND controls. 
Consequently, the highest proportion of G alleles is seen in control and the lowest is seen in CD 
dengue cases (figure 15).  
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Figure 13.  Allele Frequencies by diagnosis: rs2296414 
Figure 14.  Allele frequencies for rs34039386 
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Figure 15.  Allele Frequencies by Diagnosis: rs34039386 
3.2 HARDY-WEINBERG EQUILIBRIUM 
Observed genotype frequencies and observed allele frequencies were used to calculate expected 
genotype frequencies using the Hardy-Weinberg equilibrium equation, 
𝑝𝑝2 + 2𝑝𝑝𝑝𝑝 + 𝑝𝑝2 = 1 
Chi-squared analysis was used to determine if the sites were in Hardy- Weinberg and if 
there were any deviations within diagnosis groups. Departures from HWE could indicate errors in 
the genotyping itself, but could also suggest the presence of demographic features in the population 
(non-random mating, population substructure/admixture) as well as a selective advantage 
conferred by one genotype in the presence of dengue infection 
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3.2.1 rs2996414 
The whole sample was found to be in Hardy-Weinberg Equilibrium with regards to rs2296414. A 
non-significant p-value from chi-squared analysis showed no departure from equilibrium (table 5). 
In addition to the whole sample, both the cases and controls are in Hardy-Weinberg equilibrium 
as well when considered separately (table 5). 
Table 5.  Observed and expected genotype frequencies for sample population: rs2296414 
All Samples Cases Controls 
CC 115 88 27 
CT 59 36 23 
TT 3 3 0 
No Data 2 1 1 
Informative Total 177 127 50 
Alleles 
C 289 212 77 
T 65 42 23 
T frequency 18.36% 16.54% 23.00% 
C frequency 81.64% 83.46% 77.00% 
Expected Genotypes 
CC 117.97 88.47 29.65 
CT 53.06 35.06 17.71 
TT 5.97 3.47 2.65 
Total 177.00 127.00 50.00 
Chi-squared 
0.330528 0.954914 0.107468 
The p-value for the chi-squared test for Hardy-Weinberg equilibrium in the whole population is 
.33. For the cases it is .95, and for the controls .11. When investigated by diagnosis, the samples 
are still within Hardy-Weinberg equilibrium. No significant p-values were found when values of 
<.05 are considered significant. The observed and expected genotype frequencies as well as the 
allele frequencies and chi-squared results can be found in table 6. 
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Table 6.  Observed and expected genotype frequencies by diagnosis: rs2296414 
Observed Genotypes DF CD DHF ND 
CC 27 54 7 27 
CT 10 24 2 23 
TT 0 1 2 0 
No Data 1 0 0 1 
Informative Total: 37 79 11 50 
Alleles 
Total C Alleles 64 132 16 77 
Total T Alleles 10 26 6 23 
T frequency: 13.51% 16.46% 27.27% 23.00% 
C frequency: 86.49% 83.54% 72.73% 77.00% 
Expected Genotypes 
CC 27.7 55.1 5.8 29.6 
CT 8.6 21.7 4.4 17.7 
TT 0.7 2.1 0.8 2.6 
Total 37 79 11 50 
Chi-Squares 
0.63657 0.647512 0.199146 0.107468 
3.2.2 rs34039386 
As with the previous SNP, the whole sample is in Hardy-Weinberg equilibrium with regards to 
rs34039386. The cases and controls are also in Hardy-Weinberg for this location. The p-value of 
the chi-squared test for significance for the whole sample population is p=.72. The values for cases 
and controls are p=.99 and p=.66, respectively (table 7).  It was also found that the populations 
remain in Hardy-Weinberg equilibrium when broken down by diagnosis (table 8). No significant 
results are seen when a p-value of <.05 is considered significant.  
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Table 7.  Observed and expected genotype frequencies for sample population: rs34039386 
Observed Whole Sample Cases Controls 
GG 77 46 31 
AG 77 61 16 
AA 25 21 4 
Total 179 128 51 
Allele 
G 231 153 78 
A 127 103 24 
G frequency 64.53% 59.77% 76.47% 
A frequency 35.47% 40.23% 23.53% 
Expected 
GG 74.53 45.72 29.82 
AG 81.95 61.56 18.35 
AA 22.53 20.72 2.82 
Total 179 128 51 
Chi-Squared 
0.721691 0.994744 0.657617 
Table 8.  Observed and expected genotypes by diagnosis: rs34039386 
Observed Genotypes DF CD DHF ND TOTAL 
GG 15 27 4 31 77 
AG 16 39 6 16 77 
AA 7 13 1 4 25 
Total 38 79 11 51 179 
Alleles 
G 46 93 14 78 231 
A 30 65 8 24 127 
G frequency 0.61 0.59 0.64 0.76 
A frequency 0.39 0.41 0.36 0.24 
Expected Genotypes 
GG 13.92 27.37 4.45 29.82 77 
AG 18.16 38.26 5.09 18.35 77 
AA 5.92 13.37 1.45 2.82 25 
Total 38 79 11 51 179 
Chi-Squared 
0.764649 0.985312 0.839136 0.657617 
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3.3 ODDS RATIOS 
3.3.1 rs2994614 
Odds ratios were calculated for each site as well. The odds ratios were first calculated from the 
results of this study alone. To boost sample size and to further test the proposed association, results 
obtained from this study were combined with results of genotyping from the previous study[34]. 
In the combined test, the controls from the previous sample were used in place of combining 
control groups. This is because the controls for this sample were from a different group than the 
controls used in the previous study. The controls for this sample came from patients admitted to 
hospitals with other febrile diseases that were determined to be free of dengue. The controls used 
in the previous study were from individuals receiving a yellow fever vaccine that were determined 
to not have dengue. The controls from the previous study were used for the combined odds ratios 
because they gave a larger sample size. Odds ratios were calculated between comparisons of 
(TT+CT) and CC, and comparisons of TT and (CT+CC). This was done between cases and non-
dengue controls and between severe dengue (CD+DHF) and classic dengue (DF), as well as 
dengue hemorrhagic fever (DHF) versus all other classifications of dengue. This analysis would 
reveal whether any allele was preferentially associated with disease status, and whether this 
association showed a Mendelian dominant or recessive pattern. The only significant results 
(OR=25.5, P=.01) from this analysis were found when DHFx(CD+DF) was compared for the TT 
genotype versus the other two genotypes (table 9). No other significant results were seen when the 
novel samples were analyzed alone (table 9). 
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Table 9.  Odds ratios: rs2296414 
Dengue 
Cases 
Non-
dengue 
controls 
Odds 
Ratio 95% CI P-value 
TT+CT 39 23 .52 0.27-1.02 .056 
CC 88 27 
Dengue 
Cases 
Non-
Dengue 
Controls 
Odds 
Ratio 95% CI P-value 
TT 3.5 .5 
2.84 0.14-55.97 .49 
CT+CC 124.5 50.5 
Severe 
Dengue 
(CD+DHF) 
Classic 
Dengue 
(DF) 
Odds 
Ratio 95% CI P-value 
TT+CT 29 10 
1.28 0.55-3.00 .56 
CC 61 27 
Severe 
Dengue 
(CD+DHF) 
Classic 
Dengue 
(DF) 
Odds 
Ratio 95% CI P-value 
TT 3.5 .5 
3.00 0.15-59.53 .47 
CT+CC 87.5 37.5 
DHF DF+CD Odds Ratio 95% CI P-value 
TT+CT 4 35 
1.32 .36-4.8  .67 
CC 7 82 
DHF DF+CD Odds Ratio 95% CI P-value 
TT 2 1 
25.56 2.1-309.56   .01 
CT+CC 9 115 
When combined with the data from the previous study, a significant result (OR=1.92, 
p=.0013) was found when comparing cases and non-dengue controls. This significance was only 
seen between cases and controls and not between severe dengue and classic dengue (table 10). A 
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significant result was also carried over from the DHF versus (DF+CD) comparison. A highly 
significant p value was seen (p=.0001). 
Table 10.  Combined Odds ratios: rs2296414 
Dengue 
Cases Controls 
Odds 
Ratio 95% CI P-value 
TT+CT 135 42 
1.92 1.29-2.87 .0013 
CC 259 155 
Dengue 
Cases Controls 
Odds 
Ratio 95% CI P-value 
TT 9.5 3 
1.59 0.43-5.90 .49 
CT+CC 385.5 194 
Severe 
Dengue 
Classic 
Dengue 
Odds 
Ratio 95% CI P-value 
TT+CT 101 50 
1.52 1.00-2.30 .052 
CC 148 111 
Severe 
Dengue 
Classic 
Dengue 
Odds 
Ratio 95% CI P-value 
TT 8.5 1.5 
3.77 0.66-21.61 .14 
CT+CC 241.5 160.5 
DHF DF+CD Odds Ratio 95% CI P-value 
TT 5 4 
15.29 3.91-60.28  .0001 
CT+CC 29 356 
3.3.2 rs34039386 
As with the previous SNP, the odds ratios for rs34039386 were calculated first on their own and 
then combined with the data from the previous study. Also, as previously stated, the controls used 
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in the combined analysis were only the controls from the previous study. Dengue cases versus non-
dengue controls, severe dengue vs. classic dengue, and DHF vs. (DF+CD) were all investigated. 
A significant association was found between dengue cases and non-dengue controls (OR=2.76, 
p=.003). No significant association was found between severe dengue and classic dengue, or 
between DHF and (DF+CD). The results of the different odds ratios can be seen in table 11.  
Table 11. Odds ratios: rs34039386 
Dengue 
Cases 
Non-
Dengue 
Controls 
Odds 
Ratio 95% CI P-value 
AA+AG 82 20 
2.76 1.42-5.39 .003 GG 46 31 
Dengue 
Cases 
Non-
Dengue 
Controls 
Odds 
Ratio 95% CI P-value 
AA 21 4 
2.31 0.75-7.09 .14 
AG+GG 106 47 
Severe 
Dengue 
Classic 
Dengue 
Odds 
Ratio 95% CI P-value 
AA+AG 59 23  
1.24 0.57-2.71 .58 GG 31 15 
Severe 
Dengue 
Classic 
Dengue 
Odds 
Ratio 95% CI P-value 
AA 14 7 
.82 0.3-2.21 .68 
AG+GG 76 31 
DHF DF+CD Odds Ratio 95% CI      P-value 
AA+AG 7 75 
.98 .27-3.54 .98 
GG 4 42 
DHF DF+CD Odds Ratio 95% CI      P-value 
AA 1 20 
.48 .05-4.05   .5 
AG+GG 10 97 
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When combined with the data from the previous study, the significant result seen between 
cases and non-dengue controls is no longer apparent. No significant results were seen in the 
combined data in either the cases/controls comparison or in the severe/classic comparison. Results 
from these odds ratios can be seen in table 12.  
Table 12.  Combined Odds Ratios: r34039386 
Dengue 
Cases Controls 
Odds 
Ratio 95% CI P-value 
AA+AG 197 100 
1.18 0.81-1.70 .39 
GG 134 80 
Dengue 
Cases Controls 
Odds 
Ratio 95% CI P-value 
AA 47 33 
.74 0.45-1.20 .22 
AG+GG 284 147 
Severe 
Dengue 
Classic 
Dengue 
Odds 
Ratio 95% CI P-value 
AA+AG 132 65 
1.41 0.9-2.23 .14 
CC 79 55 
Severe 
Dengue 
Classic 
Dengue 
Odds 
Ratio 95% CI P-value 
AA 31 16 
1.12 0.58-2.14 .73 
AG+GG 180 104 
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4.0  DISCUSSION 
4.1 DEMOGRAPHIC RESULTS 
The lack of significance between sex and disease represented a departure from what was seen in 
the previous study[34] and in the cohort from which the samples were selected[32]. Both Cathcart 
and Cordeiro found that female sex was significantly associated with dengue infection in this 
cohort. This departure may just be due to random variations within the samples or may result from 
the smaller sample size of this study. It is not well-understood what the connection between sex 
and dengue infection may be, so it is difficult to speculate what may be different within this specific 
set of samples.  
4.1.1 rs2994614 Results 
The observed genotypes open up some interesting questions. For rs2296414, a slightly higher 
proportion of TT genotypes can be seen in the DHF diagnosis group, while no TTs were found in 
the control group (figure 9). Because of the low frequency of the T allele in the global population 
(.146)[30], this sample had a small enough number of the rare homozygotes to make it difficult to 
determine if this difference may represent an actual difference or if it is just caused by random 
variation in this sample. Studies with larger samples sizes should be conducted to give enough 
power for this analysis to be possible. If this pattern can be established by larger studies, it may 
suggest that the TT genotype is associated with progression to DHF or other severe forms of 
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dengue infection. As can be seen in a later section some results from this study do suggest that this 
may be the case. This supports the evidence gathered from the previous research[34].  
The presence or absence of Hardy-Weinberg equilibrium (HWE) is an important indicator 
of the accuracy of genotyping, as well as other, more complicated genetic influences. Deviations 
from HWE can indicate that a high proportion of samples were genotyped incorrectly. These 
samples were shown to be in Hardy-Weinberg for both cases and controls. Significance testing 
with chi-squared showed no deviations from HWE. When broken down by diagnosis, HWE is 
maintained throughout. It is clear that for this population, Hardy-Weinberg is maintained 
throughout. This is an important indicator that our samples were genotyped correctly in the 
majority of cases. 
Odds ratios were conducted to test if each allele at this location is acting in a dominant or 
recessive nature with relationship to disease status. A significant association was found at this SNP 
when DHF was compared to all other dengue diagnoses. It was only seen when comparing the TT 
genotype with the other genotypes. This association suggests that there may be a relationship 
present between the TT genotype and the progression to DHF.  
These results are limited, though, so it is not possible to determine what that relationship 
may be. It does open up research further into the question, however. The association between DHF 
and the TT genotype was the only significant result seen in analyzing the novel data. The test of 
the other associations may have been complicated by the very low number of TTs represented in 
this population. There were likely not enough TT genotypes present to get an accurate assessment 
of the true relationship. Because of the small sample size of the novel, this data was combined with 
data from the previous study. When analyzed, there was a significant association between cases 
and controls in relationship to the T allele (OR=1.90, p=.0013). This suggests that the T allele is 
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significantly associated in dominant manner with dengue disease. This corroborates the findings 
from the previous study which also found that the T allele was significantly associated with 
disease[34]. The significant result seen in the novel data when comparing DHF to (DF+CD) was 
also seen using the same comparisons in the combined data. A highly significant p-value was seen 
(p=.0001). This continues to support the evidence suggesting that in the case of DHF, the TT 
genotype and not just the T allele may play an important role in susceptibility. 
This association between the TT genotype and disease is supported by what is understood 
of the process of dengue virus infection of macrophages. The mutation at rs2296414 results in a 
change from threonine to asparagine in the fibronectin domain of the mannose receptor. Because 
it has been shown that the dengue virus binds to the CRD, domain changes in the fibronectin 
domain most likely do not directly affect the entry of dengue into the cell, but it is possible that 
the amino acid switch may cause a conformational change in the receptor that makes binding or 
entry of the virus more difficult, if not impossible [22, 24, 25]. Research has shown that binding 
of the dengue virus to the mannose receptor is an important piece in the process of the virus 
infecting macrophages, so changes in this receptor may represent important factors in the infection 
process[24]. 
4.1.2 RS34039386 
The SNP rs34039386 also showed some interesting results when genotypes were viewed. It can 
be seen in figure 11 that AG and AA are highest among the different dengue diagnoses, while GG 
is highest among the ND controls. This represents a possible association between the A allele and 
dengue infection. This is an interesting observation, as previous studies have found an association 
between this specific SNP and susceptibility to other infectious diseases[29]. Because a 
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relationship was seen between another infectious disease (tuberculosis) and this SNP, further 
research is definitely warranted. There may be important differences between these cases, 
however, because of the nature of the infectious diseases in question. Tuberculosis is a bacterium 
and dengue is a virus, so the mechanisms of infection and their relationship to the mannose receptor 
may be very different.  
The distribution of genotypes seen for rs34039386 was also tested to determine if it was in 
Hardy-Weinberg equilibrium. It was found to be in equilibrium overall, as well as in cases and 
controls. When broken down by diagnosis, no departures from Hardy-Weinberg were found within 
these samples. The same results can be concluded from this as from the previous site.  
Odds ratios for this SNP were also calculated. The relationship here was reversed from 
what was found at the other site with regards to the data analyzed separately and the data analyzed 
together. When the data from this study was analyzed on its own, a significant relationship was 
found between the A allele and disease (OR=2.76, p=.003). When the data was combined with the 
previous data, the association was no longer present. This is possibly because the previous study 
found no association at this site. It was speculated in that study that the fact that the population 
was out of Hardy-Weinberg for this SNP may have impacted the ability to tell if there was a true 
association present. This is supported by the fact that an association was found in a sample where 
the population was in Hardy-Weinberg equilibrium.  
An association between disease and genotype at this location is very possible because of 
the nature of the site. The SNP rs34039386 is located in exon 7 of the MCRI gene which is an exon 
that has previously been shown to have associations with susceptibility to several infectious 
diseases [27-29]. This SNP codes for part of the CRD-2 domain of the mannose receptor[25] and 
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while dengue has not been shown to bind to this specific part of the CRD, it has been shown that 
this is the region of the receptor responsible for binding the dengue virus[24]. 
4.2 LIMITATIONS 
This study has several limitations. Most importantly is the small sample size, which limits the 
power of the statistical testing and the likelihood of finding significant results. The biggest part of 
this limitation is the fact that the low frequency of the T allele of rs2296414 means that there are 
very few of these genotypes represented in these sample populations. This limits the ability to test 
for association between this genotype and disease status.  
Another important limitation is the generalizability of the study. These samples only 
represent a small population of patients from a specific location in Brazil. Dengue epidemiology 
differs markedly between different global populations. In addition, it is common for allele 
frequencies to differ significantly between different populations and different ethnic and racial 
backgrounds. Because of these variations, it is possible that associations found may be specific to 
this Brazilian population and may not be generalizable to the larger global population. Additional 
studies with more diverse ethnic and racial backgrounds will be needed to determine how these 
associations may persist across different populations. 
A third limitation is the lack of data on dengue type of dengue infection in the samples. 
This means if it was a primary dengue infection or a secondary dengue infection. Some samples 
had data on this, but it was not consistent enough across the whole data set to be looked at as a 
confounding factor or association. It is well documented that secondary infection is associated with 
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more severe disease[6]. This association was not seen in the population in this study, however[32]. 
Further studies will be necessary to test the association of genotype and infection type.  
4.3 FURTHER DIRECTIONS 
The results from this study and from the previous study suggest multiple directions that could be 
taken for further research. In addition to the obvious need for larger sample sizes and more diverse 
populations, there are many other directions to take. If more studies continue to find an association 
between these genotypes and dengue infection, there are many potential directions the research 
could take next. Haplotype and linkage analysis would more fully tell us what is happening at these 
particular SNPs and how their association with disease may be linked with other SNPs or alleles 
within the MRCI gene.  
It would also be beneficial to investigate how the genotype in these cases affects the 
phenotype of the individual. Protein analysis could give answers on if and how these SNPs may 
be changing the way dengue infects macrophages through the mannose receptor.  
As previously mentioned, it is not completely understood how dengue is internalized into 
host cells. Continuing to build understanding of that process would allow future research to better 
understand the potential mechanisms at play and how SNPs or other mutations within the mannose 
receptor or other candidates may change the viruses’ ability to bind to or be internalized into host 
cells.  
Finally, because the four serotypes are similar but distinct, there may be subtle but 
important differences between them. The host genetics that affect the susceptibility of a host to 
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one serotype may not have the same effect on the others. Studies should be done to compare the 
different serotypes’ association with these SNPs and other host genetic factors.  
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5.0  PUBLIC HEALTH SIGNIFICANCE 
Dengue is one of the fastest-spreading global infectious diseases. There is no doubt of the critical 
public health significance of this disease. While there are many important things about this disease 
that make it an important focus of research and development, perhaps the most important is its 
unique relationship to global climate, shifting climate patterns, and global travel. Because dengue 
is a mosquito-borne disease, its spread and relevance as a global infection is directly tied into the 
habitat of the Aedes mosquito, its primary vector. Another area of public health significance is the 
difficulty and challenges of vaccine development for dengue. Because of this, a deeper 
understanding of all factors that play a part in infection (including host genetics) is critical for 
further developing an effective and safe vaccine.  
5.1 DENGUE AND CLIMATE CHANGE 
Over the past several decades, shifting global climate has allowed for the expansion of the range 
of the primary vectors for dengue, Aedes aegypti and Aedes albopictus, to almost all areas at lower 
and middle latitudes[13]. These increased ecological niches for the vectors of dengue and other 
disease carried by these mosquitos poses a significant public health risk, as a large portion of the 
world population lives in these areas. Some estimates suggest that close to 4 billion people live in 
areas that put them at risk for dengue[2]. This number may continue to grow as climate shifts and 
global warming continues. In the past decade, dengue has been found in locations where it had 
previously been absent. Beginning in 2009, sporadic outbreaks dengue began in Monroe County 
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in southern FL. It was determined that these cases were not all travel-associated and that local 
transmission of the disease was occurring[36]. Local Aedes aegypti mosquitos were found to be 
infected with strains of dengue that were linked to strains from Nicaragua, Mexico, and Puerto 
Rico. Dengue is endemic in these areas, and the potential for continued introduction to the local 
mosquito population through travel is very high[36]. 
Another worrying trend is the spreading habitat of the other Aedes species able to transmit 
dengue, Aedes albopictus, or the Asian tiger mosquito. This mosquito is not as competent a vector 
for dengue as its cousin, but studies suggest that it is able to outcompete the aegypti species as 
larva. It is an incredibly aggressive mosquito that bites throughout the day and prefers urban areas 
and humans as its blood meals[14]. The range of the Asian tiger mosquito is also continuing to 
expand. It can be found as far north as New Jersey and New York, and as far west as western 
Pennsylvania. Because of the increasing range of this vector, the potential for introduction of the 
virus into the local mosquito populations is high. Global travel has made it easier for diseases to 
spread quickly and easily from distant locations. The fact that the closest locally-acquired dengue 
cases are in southern Florida may not stop the disease from becoming established among more 
mosquito populations within the United States.  
5.2 VACCINE DEVELOPMENT CHALLENGES 
Vaccine development for dengue is very challenging. The main goal of the development of an 
effective vaccine for dengue is the necessity for it to protect against all strains. This is critical 
because of the lack of a cross-reactive response from the immune system between the different 
stains and because of the theory of antibody-dependent enhancement. A vaccine that does not 
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provide effective protection against all strains may protect well against one strain, but cause a 
much more serious reaction on a secondary infection with a different strain. Because of these 
challenges, no effective vaccine is yet available despite several trials[37], and vaccine targets are 
a growing area of research. The mannose receptor is considered an important vaccine target that 
may be able to increase the immunogenicity of vaccine antigens because of its ability to internalize 
targets and load them onto MHC complexes[22]. A better understanding of the effects of 
polymorphisms within the MRCI gene may be an important factor in designing an effective 
vaccine.  
5.3 GLOBAL BURDEN 
Dengue’s increasing global burden and the lack of a vaccine make research into this disease an 
important focus of continuing public health research. Genetic research into host factors that affect 
the disease provide an interesting and increasingly important area of research. A better 
understanding of the complex factors that determine a person’s susceptibility to diseases may allow 
researchers to create more specific and targeted treatments, and may lead to the development of a 
vaccine that is effective and safe across all serotypes, as well as the diverse populations at risk.   
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6.0  CONCLUSION 
Dengue is an important and emerging infectious disease that has critical public health implications 
on a global scale. Detailed and ongoing research on the dynamic nature of this disease is important 
in continuing to understand how it spreads globally and infects its hosts. This study found a 
significant association between both of the SNPs investigated and dengue for certain tests. The 
rs2296414 SNP was found to be in Hardy-Weinberg equilibrium. The population was found to be 
in Hardy-Weinberg equilibrium with regards to cases and controls. When broken down by disease 
status, no departure from equilibrium was seen. A significant association was found between DHF 
and the TT genotype. A previous study (Cathcart) found an association between rs2296414 and 
dengue infection and an association between rs2296414 and severe disease outcomes. When data 
from this study was combined with data from the previous study, a significant association was 
seen between cases and controls (P=.0013). No significant association was seen when comparing 
severe dengue and classic dengue in either the novel samples or the combined samples. 
As with rs2296414 Hardy-Weinberg equilibrium was tested using chi-squared analysis to 
determine significance for rs34039386. The population was found to be in Hardy-Weinberg 
equilibrium, as were the populations when broken down by disease status. Odds ratios were also 
calculated for rs34039386, and some significant results were found. There was a significant 
association found between the A allele and disease that indicates that it works in a dominant 
manner. This finding was not duplicated when the data was combined with the previous study’s 
results. This may be because the previous study population was out of Hardy-Weinberg 
equilibrium for this SNP.  
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This study, along with previous work, opens up an important area of research that has 
received limited attention. Further in-depth analysis with larger sample sizes and from more 
diverse global populations may find that these SNPs do have an effect on dengue infection or 
dengue severity, or it may be found that there are other critical SNPs within MRCI and other similar 
genes. Developing this research more may lead to more avenues for developing vaccines to dengue 
and designing more effective treatments.   
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